• Ganetespib (STA-9090): Elevating Translational Oncology b...

  2026-01-20

  Discover how Ganetespib (STA-9090), a triazolone-containing, non-geldanamycin Hsp90 inhibitor, is catalyzing a new era in translational oncology. This thought-leadership article integrates mechanistic insight, recent discoveries in regulated cell death, and strategic guidance for researchers. Learn how Ganetespib's unique ATP-competitive action affects oncogenic client proteins, intersects with emerging models of cell fate control such as NINJ1-mediated membrane rupture, and unlocks next-generation preclinical strategies for cancer research. With contextual links to APExBIO's authoritative product and in-depth literature, this comprehensive guide reframes the experimental and clinical landscape of Hsp90 inhibition.

• KPT-330 (Selinexor): Selective CRM1 Inhibitor for Cancer ...

  2026-01-20

  KPT-330 (Selinexor), a selective CRM1 inhibitor, disrupts nuclear export and induces apoptosis in cancer cells. This agent demonstrates benchmark efficacy in preclinical models of non-small cell lung cancer (NSCLC), pancreatic cancer, and triple-negative breast cancer (TNBC). APExBIO’s KPT-330 is a validated tool for mechanistic oncology studies targeting the CRM1 pathway.

407 records 28/28 page Previous First page 上5页 262728